Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with oral thrush or hairy leukoplakia and less than 400 CD4 lymphocytes per mm3. To determine whether the long-term toxicities associated with daily dapsone in this population are tolerable.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jacobus Pharmaceutical
• Treatments: Dapsone

Criteria

Inclusion Criteria

The patient must have HIV positive antibody test and presence of oral thrush or hairy leukoplakia.

• Patient must be willing and able to sign informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.

• Prophylaxis for PCP in preceding 3 months.

• Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.

• Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative dermatitis during treatment with dapsone.

• History of poor compliance.

Concurrent Medication:

Excluded:

• Zidovudine (AZT).

Patients with the following are excluded:

• Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.

• Prophylaxis for PCP in preceding 3 months.

• Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.

• Concurrent or prior therapy with zidovudine (AZT).

• Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative dermatitis during treatment with dapsone.

• History of poor compliance.

Prior Medication:

Excluded:

• Zidovudine (AZT).